Phase III Double-Blind, Placebo-Controlled, Prospective Randomized Trial of Adjuvant Tamoxifen vs. Tamoxifen and Fenretinide in Postmenopausal Women with Positive Receptors (EB193): An Intergroup Trial Coordinated by the Eastern Cooperative Oncology Group

Lignende værker

• A Randomized Trial of Adjuvant Chemotherapy and Tamoxifen Timing in Postmenopausal, Endocrine-Responsive, Node-Positive Breast Cancer
  af: Albain, Kathy S., et al.
  Udgivet: (2009)
• Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
  af: Bertelli, G., et al.
  Udgivet: (2010)
• Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
  af: Brauch, Hiltrud, et al.
  Udgivet: (2013)
• Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
  af: Tevaarwerk, Amye J., et al.
  Udgivet: (2014)
• Randomized Double-Blind 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women
  af: Decensi, Andrea, et al.
  Udgivet: (2009)